

Haematologica
HAEMATOL/2019/220194
Version 4

IGHV mutational status and outcome for patients with chronic
lymphocytic leukemia upon treatment: a Danish nationwide
population-based study

Emelie Curovic Rotbain, Henrik Frederiksen, Henrik Hjalgrim, Klaus Rostgaard, Gudrun Jakupsdottir Egholm, Banafsheh Zahedi, Christian Bjørn Poulsen, Lisbeth Enggaard, Caspar da Cunha-Bang, and Carsten Utoft Niemann

Disclosures: ECR received support from Janssen within this work. ECR received travel grants from Abbvie and Janssen. HF received support outside this work from Alexion, Gilead, Abbvie, Janssen Pharmaceuticals and Novartis. CBP received consultancy fees and/or travel grants from Roche, Abbvie, Gilead and Janssen. LE received consultancy fees or travel grants from Abbvie, Gilead and Janssen. CN received support from Novo Nordisk Foundation NNF16OC0019302 within this work. CN received support, consultancy fees or travel grants from Abbvie, Gilead, Janssen, Roche, CSL Behring, Acerta, Genmab, Sunesis and Astra Zeneca outside this work. HH, KR, GJE, BZ and CCB had no conflicts of interest to disclose.

Contributions: ECR, HF, HH, KR, CCB and CN designed the study. ECR and CCB analyzed the data. ECR, HF, CCB and CN wrote the first draft of the paper. ECR, GJE and BZ collected data. HF, CN, CBP and LE contributed patient records. All authors contributed to the writing of the manuscript and revision and approved the final paper. CCB and CN contributed equally to the study.